Back to News
Market Impact: 0.42
FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA will maintain its hold on enrollment of new U.S. patients in Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial of evenamide. The continued clinical-trial enrollment restriction delays progress for the schizophrenia-treatment candidate and represents a material regulatory setback for Newron.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.58
More News
- Anthropic CEO Amodei to have dinner with Trump at White House
- Here are the 4 big things we're watching in the stock market in the week ahead
- Mike Waltz: US offered to sell Iran uranium for civilian programme
- Trump to have dinner with Anthropic CEO Amodei at the White House, Axios reports
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
- IAEA Says Iran Nuclear Oversight Can Resume Fast
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Software for Buy-Side Teams: Build the Research Stack
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit